Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients

2007 ◽  
Vol 59 (3) ◽  
pp. 177-186 ◽  
Author(s):  
Justin P. Rubio ◽  
Melanie Bahlo ◽  
Jim Stankovich ◽  
Rachel K. Burfoot ◽  
Laura J. Johnson ◽  
...  
2004 ◽  
Vol 63 (3) ◽  
pp. 237-247 ◽  
Author(s):  
H.F. Harbo ◽  
B.A. Lie ◽  
S. Sawcer ◽  
E.G. Celius ◽  
K.-Z. Dai ◽  
...  

Genomics ◽  
1998 ◽  
Vol 47 (3) ◽  
pp. 372-382 ◽  
Author(s):  
Takashi Shiina ◽  
Gen Tamiya ◽  
Akira Oka ◽  
Tetsushi Yamagata ◽  
Naomi Yamagata ◽  
...  

1993 ◽  
Vol 38 (1) ◽  
pp. 47-53 ◽  
Author(s):  
Corine Vernet ◽  
Marie-Th�r�se Ribouchon ◽  
Giovanna Chimini ◽  
Anne-Marie Jouanolle ◽  
Issa Sidib� ◽  
...  

2008 ◽  
Vol 1 (1) ◽  
pp. 370-372 ◽  
Author(s):  
E.M. Schwartz-Jungl ◽  
E.M. Dauber ◽  
S. Wenda ◽  
G. Dorner ◽  
B. Glock ◽  
...  

2008 ◽  
Vol 17 (8) ◽  
pp. 2074-2088 ◽  
Author(s):  
NATASJA G. DE GROOT ◽  
CORRINE M. C. HEIJMANS ◽  
NANINE DE GROOT ◽  
NEL OTTING ◽  
ANNEMIEK J. M. DE VOS-ROUWELER ◽  
...  

1990 ◽  
Vol 85 (5) ◽  
Author(s):  
DeirdreK. Lord ◽  
I. Dunham ◽  
R.Duncan Campbell ◽  
Adrian Bomford ◽  
Tom Strachan ◽  
...  

2018 ◽  
Vol 76 (10) ◽  
pp. 697-704 ◽  
Author(s):  
Lineu Cesar Werneck ◽  
Paulo José Lorenzoni ◽  
Cláudia Suemi Kamoi Kay ◽  
Rosana Herminia Scola

ABSTRACT Objective: To investigate the potential relationship between the human leukocyte antigen (HLA) type (class I and II) and the response to several disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS). Methods: We analyzed clinical data of 87 patients with MS at the beginning and end of each type of DMT including the disease duration, Expanded Disability Status Scale and Multiple Sclerosis Severity Score (MSSS). Genotyping of HLA-DRB1, HLA-DPB1, HLA-DQB1, HLA-A, HLA-B and HLA-C alleles were identified using high-resolution techniques. Statistical correlation between the HLA type and response to DMTs was done using the initial and final MSSS. Results: Statistical relationships (p < 0.05) were found for only 15 of 245 alleles tested. There was a reduction in the MSSS for patients treated with corticosteroids (DRB1*15:01, DPB1*04:01, DQB1*02:01 and DQB1*03:01), azathioprine (DRB1*03:01, DPB1*04:01, DQB1*03:02, DQB1*06:02, HLA-C*07:02), interferon β-1a 22 mcg (DRB1*11:04, DQB1*03:01 and DQB1*03:02), interferon β-1a 30 mcg (DPB1*02:01, HLA-C*05:01) and interferon β-1b (DQB1*02:01). Conclusion: These findings suggest a few relationships between the HLA and response to DMTs in the disability for some types of HLA class I and II alleles in a specific subset of MS patients.


Genomics ◽  
2011 ◽  
Vol 97 (4) ◽  
pp. 223-234 ◽  
Author(s):  
Hoyoung Chung ◽  
Matthew Charles McClure

Sign in / Sign up

Export Citation Format

Share Document